Product Information
CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.7462 per EA under NDC 16571069401. Its NADAC has been published 221 times since Jun 1, 2022.
FDA first approved this application on Jan 25, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
50; 200; 200 mg/1; mg/1; mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571069401
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
CARBIDOPA; ENTACAPONE; LEVODOPAApproval Type
Generic (ANDA)
FDA Application
ANDA213212FDA Approved
1/25/2022
TE Code
AB
On Market Since
8/5/2021
Pharmacological Classes
Price Statistics
The NADAC for CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB has been published 221 times since Jun 1, 2022, and over the history we have for it it has declined 22.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7462 per EA |
|---|---|
| All-time high | $0.9950 (Dec 14, 2022) |
| All-time low | $0.6636 (Aug 21, 2024) |
| 52-week high | $0.7988 |
| 52-week low | $0.7126 |
| Median price | $0.7867 |
| Average price | $0.8092 |
| Largest weekly change | +25.1% (Sep 20, 2023) |
| Weeks tracked | 221 |
| Tracking since | Jun 1, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the CARBIDOPA, LEVODOPA AND ENTACAPONE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB, manufactured by Rising Pharma Holdings Inc., is $0.7462 per EA (NDC 16571069401), effective Aug 19, 2026.
How has the price of CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB changed over time?
Over the history we have for it, the NADAC for CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB has declined 22.7%. It has been tracked across 221 weekly CMS publications since Jun 1, 2022.
What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB?
Since Jun 1, 2022, the NADAC for CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB has ranged from a low of $0.6636 (Aug 21, 2024) to a high of $0.9950 (Dec 14, 2022), with a median of $0.7867 per EA.
Are there cheaper alternatives to CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB?
CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB (NDC 16571069401) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.